U01 DK061058/DK/NIDDK NIH HHS/United States[Grant Number] - Search Results

Year	Number of Results
2009	2
2011	4
2012	5
2013	12
2014	12
2015	15
2016	18
2017	18
2018	18
2019	17
2020	21
2021	11
2022	9
2023	7
2024	6
2025	16
2026	6

1

An Anti-CD3 Antibody, Teplizumab, in Relatives at Risk for Type 1 Diabetes.

Herold KC, Bundy BN, Long SA, Bluestone JA, DiMeglio LA, Dufort MJ, Gitelman SE, Gottlieb PA, Krischer JP, Linsley PS, Marks JB, Moore W, Moran A, Rodriguez H, Russell WE, Schatz D, Skyler JS, Tsalikian E, Wherrett DK, Ziegler AG, Greenbaum CJ; Type 1 Diabetes TrialNet Study Group. Herold KC, et al. N Engl J Med. 2019 Aug 15;381(7):603-613. doi: 10.1056/NEJMoa1902226. Epub 2019 Jun 9. N Engl J Med. 2019. PMID: 31180194 Free PMC article. Clinical Trial.

2

Teplizumab improves and stabilizes beta cell function in antibody-positive high-risk individuals.

Sims EK, Bundy BN, Stier K, Serti E, Lim N, Long SA, Geyer SM, Moran A, Greenbaum CJ, Evans-Molina C, Herold KC; Type 1 Diabetes TrialNet Study Group. Sims EK, et al. Sci Transl Med. 2021 Mar 3;13(583):eabc8980. doi: 10.1126/scitranslmed.abc8980. Sci Transl Med. 2021. PMID: 33658358 Free PMC article. Clinical Trial.

3

Teplizumab induces persistent changes in the antigen-specific repertoire in individuals at risk for type 1 diabetes.

Lledó-Delgado A, Preston-Hurlburt P, Currie S, Clark P, Linsley PS, Long SA, Liu C, Koroleva G, Martins AJ, Tsang JS, Herold KC. Lledó-Delgado A, et al. J Clin Invest. 2024 Aug 13;134(18):e177492. doi: 10.1172/JCI177492. J Clin Invest. 2024. PMID: 39137044 Free PMC article. Clinical Trial.

4

Fine-mapping, trans-ancestral and genomic analyses identify causal variants, cells, genes and drug targets for type 1 diabetes.

Robertson CC, Inshaw JRJ, Onengut-Gumuscu S, Chen WM, Santa Cruz DF, Yang H, Cutler AJ, Crouch DJM, Farber E, Bridges SL Jr, Edberg JC, Kimberly RP, Buckner JH, Deloukas P, Divers J, Dabelea D, Lawrence JM, Marcovina S, Shah AS, Greenbaum CJ, Atkinson MA, Gregersen PK, Oksenberg JR, Pociot F, Rewers MJ, Steck AK, Dunger DB; Type 1 Diabetes Genetics Consortium; Wicker LS, Concannon P, Todd JA, Rich SS. Robertson CC, et al. Nat Genet. 2021 Jul;53(7):962-971. doi: 10.1038/s41588-021-00880-5. Epub 2021 Jun 14. Nat Genet. 2021. PMID: 34127860 Free PMC article.

5

Trajectory of beta cell function and insulin clearance in stage 2 type 1 diabetes: natural history and response to teplizumab.

Galderisi A, Sims EK, Evans-Molina C, Petrelli A, Cuthbertson D, Nathan BM, Ismail HM, Herold KC, Moran A. Galderisi A, et al. Diabetologia. 2025 Mar;68(3):646-661. doi: 10.1007/s00125-024-06323-0. Epub 2024 Nov 19. Diabetologia. 2025. PMID: 39560746 Free PMC article. Clinical Trial.

6

IA-2A positivity increases risk of progression within and across established stages of type 1 diabetes.

Sims EK, Cuthbertson D, Ferrat LA, Bosi E, Evans-Molina C, DiMeglio LA, Nathan BM, Ismail HM, Jacobsen LM, Redondo MJ, Oram RA, Sosenko JM. Sims EK, et al. Diabetologia. 2025 May;68(5):993-1004. doi: 10.1007/s00125-025-06382-x. Epub 2025 Feb 28. Diabetologia. 2025. PMID: 40016443 Free PMC article.

7

Activated polyreactive B cells are clonally expanded in autoantibody positive and patients with recent-onset type 1 diabetes.

Nicholas CA, Tensun FA, Evans SA, Toole KP, Prendergast JE, Broncucia H, Hesselberth JR, Gottlieb PA, Wells KL, Smith MJ. Nicholas CA, et al. Cell Rep. 2025 Apr 22;44(4):115425. doi: 10.1016/j.celrep.2025.115425. Epub 2025 Mar 19. Cell Rep. 2025. PMID: 40117290 Free PMC article.

8

Type 1 Diabetes TrialNet: Leading the Charge in Disease Prediction, Prevention, and Immunotherapeutic Mechanistic Understanding.

Jacobsen LM, Felton JL, Nathan BM, Speake C, Krischer J, Herold KC. Jacobsen LM, et al. Diabetes Care. 2025 Jul 1;48(7):1112-1124. doi: 10.2337/dc24-2908. Diabetes Care. 2025. PMID: 40272284 Free PMC article. Review.

9

Novel Approach for Assessing Outcomes of Type 1 Diabetes Prevention Trials Over a Fixed Time Interval.

Sims EK, Russell WE, Cuthbertson D, Skyler JS, Jacobsen LM, Ismail HM, Redondo MJ, Nathan BM, Carr ALJ, Taylor PN, Dayan CM, Galderisi A, Herold KC, Sosenko JM. Sims EK, et al. Diabetes. 2025 Nov 1;74(11):2101-2110. doi: 10.2337/db25-0310. Diabetes. 2025. PMID: 40877213 Free PMC article. Clinical Trial.

10

Contrasting Adult and Pediatric Populations in a Cohort of At-Risk Relatives in The T1D TrialNet Pathway to Prevention Study.

Templeman EL, Ferrat LA, Thomas N, Speake C, Wherrett DK, Sherr J, Wentworth JM, Redondo MJ, Parik HM, Felton JL, Evans-Molina C, Sosenko J, You L, Oram RA, Sims EK. Templeman EL, et al. Diabetes Care. 2025 Sep 1;48(9):1571-1580. doi: 10.2337/dc25-0192. Diabetes Care. 2025. PMID: 40694568

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My Custom Filters

Results by year

Publication date

Text availability

Article attribute

Article type

Article Language

Species

Sex

Age

Other

171 results

Results by year

Search Page

Filters

My Custom Filters

Results by year

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

171 results

Results by year